EUVIMEDEUVIMED entdecken
Crossref

Highly Specific Cytokine Receptor‐Targeting Chimeras for Targeted Membrane Protein Degradation and Sensitization of Osimertinib in EGFR‐Mutated Non‐Small‐Cell Lung Cancer

Jiawei Wu, Qianqian Gao, Qing Xia, Yaru Wang, Zixuan Zheng, Axin He, Yu Liu, Yang Yang, Yanyan Miao iD, Da Han iD

Advanced Materials · 2025

DOI: 10.1002/adma.202504050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Jiawei Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. Hauptthemen laut MEDLINE: Acrylamides, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Aniline Compounds. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Key Technologies Research and Development Program, the National Science Foundation for Distinguished Young Scholars of China, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ability of cytokine receptors to mediate the internalization of targets in lysosomes positions them as specific and effective effectors for protein degradation strategies. However, challenges remain, including the potential unintended activation of cell‐proliferation‐related cytokine receptors, as well as limitations in programmability and structural flexibility of protein degradators. In this work, a CXCR7‐targeting chimera (AP‐CRTAC) that functions as a CXCR7 inducer by covalently linking a membrane protein‐targeting aptamer with a mutant‐CXCL12 mimic peptide is developed. This peptide selectively binds to CXCR7 without activating CXCR4. The AP‐CRTAC, which incorporates various aptamer forms from DNA, RNA, or even bispecific aptamers, has shown significant efficacy in degrading one or more proteins or protein mutants on the cell surface. Moreover, the AP‐CRTAC constructed with a 2′ F‐pyrimidine‐modified RNA aptamer targeting EGFR effectively degrades various EGFR activating mutations. Notably, AP‐CRTAC enhances the sensitivity of the L858R/T790M/C797S triple mutant lung cancer cells, which are resistant to current EGFR‐targeted therapies, to the third‐generation EGFR inhibitor osimertinib in both in vitro and in vivo settings. This research introduces an engineered CXCR7 inducer with high specificity and programmability for the targeted degradation of cell surface proteins, while minimizing unwanted side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesCarcinoma, Non-Small-Cell LungLung NeoplasmsAniline CompoundsAntineoplastic AgentsHumansErbB ReceptorsAnimalsProteolysisCell Line, TumorMutationReceptors, CXCRMiceAptamers, NucleotideIndolesPyrimidines

Stichwörter der Autor:innen

CXCR7EGFRaptamercancer therapytargeted protein degradation

Substanzen

ErbB ReceptorsAcrylamidesosimertinibAniline CompoundsReceptors, CXCRAptamers, NucleotideACKR3 protein, humanEGFR protein, humanAntineoplastic AgentsIndoles

Autor:innen und Institutionen

  • Institute of Molecular Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, P. R. China.
  • Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.

ORCID-Profile: Yanyan Miao, Da Han

Förderung

  • Key Technologies Research and Development Program
  • the National Science Foundation for Distinguished Young Scholars of China
  • the National Natural Science Foundation of China
  • the State Key Laboratory of Fine Chemicals, Dalian University of Technology
  • Shanghai Municipal Education Commission- Gaofeng Clinical Medicine Grant Support
  • Program of Shanghai Academic Research Leader
  • the Foundation of National Facility for Translational Medicine (Shanghai)

Zitieren

APA

Wu, J., Gao, Q., Xia, Q., Wang, Y., Zheng, Z., He, A., Liu, Y., Yang, Y., Miao, Y., & Han, D. (2025). Highly Specific Cytokine Receptor‐Targeting Chimeras for Targeted Membrane Protein Degradation and Sensitization of Osimertinib in EGFR‐Mutated Non‐Small‐Cell Lung Cancer. Advanced Materials. https://doi.org/10.1002/adma.202504050

Vancouver

Wu J, Gao Q, Xia Q, Wang Y, Zheng Z, He A, et al. Highly Specific Cytokine Receptor‐Targeting Chimeras for Targeted Membrane Protein Degradation and Sensitization of Osimertinib in EGFR‐Mutated Non‐Small‐Cell Lung Cancer. Advanced Materials. 2025. doi:10.1002/adma.202504050

BibTeX
@article{Wu2025,
  author = {Wu, Jiawei and Gao, Qianqian and Xia, Qing and Wang, Yaru and Zheng, Zixuan and He, Axin and Liu, Yu and Yang, Yang and Miao, Yanyan and Han, Da},
  title = {Highly Specific Cytokine Receptor‐Targeting Chimeras for Targeted Membrane Protein Degradation and Sensitization of Osimertinib in EGFR‐Mutated Non‐Small‐Cell Lung Cancer},
  journal = {Advanced Materials},
  year = {2025},
  doi = {10.1002/adma.202504050}
}
Kostenlos starten →